{"blog": [], "keywords": [{"value": "Medicare", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Presidential Election of 2016", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/02/02/upshot/the-real-reason-medicare-is-a-lousy-drug-negotiator-it-cant-say-no.html", "document_type": "article", "byline": {"person": [{"lastname": "SANGER-KATZ", "firstname": "Margot", "role": "reported", "organization": "", "rank": 1}], "original": "By MARGOT SANGER-KATZ"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/02/01/upshot/02up-drugs/02up-drugs-thumbWide.jpg", "legacy": {"wide": "images/2016/02/01/upshot/02up-drugs/02up-drugs-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/02/01/upshot/02up-drugs/02up-drugs-articleLarge-v6.jpg", "legacy": {"xlarge": "images/2016/02/01/upshot/02up-drugs/02up-drugs-articleLarge-v6.jpg", "xlargeheight": "722", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 722}, {"url": "images/2016/02/01/upshot/02up-drugs/02up-drugs-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/02/01/upshot/02up-drugs/02up-drugs-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "The Upshot", "word_count": "845", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Experts on the U.S. pharmaceutical market aren\u2019t optimistic that letting the government play drug negotiator would mean lower costs.", "pub_date": "2016-02-02T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "The Upshot", "print_headline": "Weak Negotiating Position: Medicare Often Can\u2019t Say No", "main": "The Real Reason Medicare Is a Lousy Drug Negotiator: It Can\u2019t Say No", "content_kicker": "Public Health"}, "print_page": "3", "snippet": "Experts on the U.S. pharmaceutical market aren\u2019t optimistic that letting the government play drug negotiator would mean lower costs.", "_id": "56b0691238f0d84912559437", "slideshow_credits": null, "abstract": "The Upshot; experts who study American pharmaceutical market counter arguments from presidential candidates, both Republican and Democrat, that prescription drug prices could be cut if federal government directly negotiated with drug manufacturers in pricing Medicare drug plans. "}